The Multimeric Universal Influenza Vaccine: BVX-M001
BiondVax’s Universal Flu Vaccine, the Multimeric-001, represents a quantum leap in the flu vaccine arena, as it is based on a proprietary combination of conserved non-changing epitopes, or peptides, common to practically all existing and future flu virus strains, including both seasonal and pandemic flu strains such as the avian and swine flu, regardless of their antigenic drift and shifts.
These epitopes activate both arms of the immune system (cellular and humoral), providing the broadest possible protection against infection by triggering fast and effective clearance of existing and future influenza strains from the body.
The Multimeric-001 Universal Vaccine is a single formulation consisting of nine conserved linear epitopes in triplicate. The epitopes selected are taken from Hemagglutinin (HA), Nucleoprotein (NP) and Matrix (M) proteins, therefore ensuring high antigen content.
This vaccine is expected to offer several advantages:
A single recombinant protein preparation that includes all the epitopes;
Multiple copies of the conserved influenza;
Additional conserved influenza epitopes
BiondVax’s vaccine has demonstrated greater efficacy levels, and a much wider scope of virus strain coverage, than existing vaccines. In addition, the Multimeric-001 is expected to provide longer-term protection than any other commercially available vaccine in the market.
This Universal Flu Vaccine has the potential to revolutionize the entire flu vaccine industry. Our vaccine is not strain- or season-dependent. It promises to provide long lasting (BiondVax believes for 3-5 years) and broad protection against existing and future influenza strains including the highly pathogenic Avian flu and Swine flu. Moreover, a single formulation will provide the first year-round vaccination. With our vaccine, mass production planning will be possible as well as on-demand worldwide distribution.
